We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

60 hedge funds and large institutions have $37.2M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

289% more call options, than puts

Call options by funds: $183K | Put options by funds: $47K

4% more capital invested

Capital invested by funds: $35.7M → $37.2M (+$1.52M)

6% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 17

14% less funds holding

Funds holding: 7060 (-10)

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

Holders
60
Holders Change
-10
Holders Change %
-14.29%
% of All Funds
1.74%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
16
Reduced
17
Closed
12
Calls
$183K
Puts
$47K
Net Calls
+$136K
Net Calls Change
-$80K
Name Holding Trade Value Shares
Change
Change in
Stake
TA
76
Teachers Advisors
New York
-$1K

FRTX Hedge Fund Activity: Q3 2014 in Review

60 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2014, worth a combined $37.2M — up 4.3% from $35.7M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of FRTX and 2 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 16 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $6.75M. The largest seller was Northern Trust, cutting an estimated $750K.

  • 60 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2014, down from 70 in Q2 2014.
  • Funds reported $37.2M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2014, up 4.3% quarter-over-quarter.
  • 2 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2014 and 12 closed out, a net change of -10 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2014 was RA Capital Management, an estimated $6.75M added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2014 was Northern Trust, an estimated $750K sold.

Based on aggregated 13F filings for Q3 2014.